Dr Reddy's launches allergy relief tablets in US
New Delhi: Drug firm Dr Reddy's Laboratories has launched levocetirizine dihydrochloride tablets, used for relieving allergies, in the US market.
In a BSE filing, Dr. Reddy's Laboratories said it had "launched levocetirizine dihydrochloride tablets USP, 5 mg, an over-the-counter therapeutic equivalent generic version of UCB's Xyzal allergy tablets, in the US market as approved by the US Food and Drug Administration (USFDA)."
Levocetirizine dihydrochloride tablets are used for 24-hour relief of allergy symptoms such as watery eyes, runny nose, itching eyes/nose and sneezing.
According to IRI sales data, Xyzal allergy tablets had sales of about USD 71 million in the US market for the 12-month period ended January 2018.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd